Not pregnant and not nursing; therefore, for women of childbearing potential only, a negative (if your test schedule specifically indicates a urine or serum pregnancy test, add that information at this point) pregnancy test done =<  days prior to registration is required
Women of childbearing potential must have a negative serum pregnancy test within  days prior to study entry
Serum or urine pregnancy test must be negative in premenopausal women within  days of randomization, or in women with amenorrhea of less than  months at time of randomization.
Pregnant women, or women of childbearing potential without a negative pregnancy test within  days prior to randomization.
Pregnant or lactating women; a negative pregnancy test in women of childbearing potential must be documented within  days before the first dose of study medication
Negative pregnancy test for women of childbearing potential (<  years of age) as per institutional policy
Negative serum pregnancy test in women of childbearing potential (WOCBP)
A negative pregnancy test =<  days prior to treatment for premenopausal women and for women <  year after the onset of menopause
Negative serum pregnancy test within  days prior to study treatment in premenopausal women and women less than (<)  months after menopause
Negative serum/urine pregnancy test (for women of childbearing potential)
Positive pregnancy test; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued; negative serum pregnancy test will be required for women of childbearing potential
Negative pregnancy test by urine or serum or waiver of pregnancy testing per local institutional policy within  days prior to randomization according to local standards for women of childbearing potential
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the -hour period prior to the first dose of study drug.
Women of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative serum pregnancy test prior to the initiation of radiation therapy
Negative serum pregnancy test within  days prior to study treatment in premenopausal women and women <=  years after menopause
Women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to the start of the study
Women of childbearing potential (WOCBP) must have negative urine pregnancy test within  days of day  (D) of treatment
Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study
Negative serum pregnancy test within  days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year
Women of childbearing potential who are not using an effective method of contraception are excluded. Women of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to administration of SRS
Pregnant or lactating, or intending to become pregnant during the study\r\n* Women of childbearing potential must have a negative serum pregnancy test result within  days prior to initiation of study drug
Negative serum pregnancy test within  days of commencement of treatment in women of childbearing potential
Women of childbearing potential must have a negative serum or urine pregnancy test within - days prior to enrollment
Women of childbearing potential must have a negative serum or urine pregnancy test.
Non pregnant and non-nursing women; women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrolment
Women of childbearing potential must have negative pregnancy test prior to initiating study treatment.
Women of childbearing potential must have a negative serum or urine pregnancy test within  day prior to administration of the first dose of chemotherapy
Women of childbearing potential must have a negative serum or urine pregnancy test at time of screening and confirmed within  days prior to treatment; women not of child-bearing potential will be defined as all women older than age  and anovulatory for  months
Negative serum pregnancy test within  days prior to cycle /day  for women of childbearing potential
Urine pregnancy test is negative for women of childbearing potential, within  days before study treatment
Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
A negative urine pregnancy test is required within  week for all women of childbearing potential prior to enrolling on this trial
DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within  days prior to stem cell mobilization
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to treatment; women not of child-bearing potential will be defined as all women older than age  and anovulatory for  months
Women of childbearing potential must have a negative urine or blood pregnancy test within  days of study enrollment
Negative serum pregnancy test within =<  days prior to the first dose of study drug, for women of childbearing potential only
Pregnant or breast-feeding patients; women of childbearing potential (WOCBP) must have a serum pregnancy test performed a maximum of  days before the start of study treatment, and a negative result must be documented before the start of study treatment
Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within  days prior to randomization, irrespective of the method of contraception used, are excluded from this study; breastfeeding must be discontinued prior to study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to registration; women of non-childbearing potential are defined as those who have no uterus, ligation of the fallopian tubes, or permanent cessation of ovarian function due to ovarian failure or surgical removal of the ovaries; all others are considered women of child bearing potential
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrollment
Negative urine or serum pregnancy test for women of childbearing potential
Pregnant or breast feeding women are excluded from participating in this study; WOCBP must have a negative serum pregnancy test within  days of the first administration of decitabine
Women of childbearing potential must have a negative pregnancy test within  days of starting treatment
A negative pregnancy test (only for women of childbearing potential [WOCBP])
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Women of childbearing potential must have a negative urine or serum pregnancy test within  days of study entry
Women of childbearing age must have a negative serum pregnancy test to meet eligibility per Duke policy
PHASE I: Negative urine pregnancy test =<  days prior to course  day  (CD) (women of childbearing potential only)
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to treatment
Women of childbearing potential must have a negative qualitative serum pregnancy test =<  weeks prior to study entry
Negative urine or serum pregnancy test done =<  days prior to computed tomography (CT) simulation, for women of childbearing potential only
Negative serum pregnancy test within  days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= year
Pregnant and breastfeeding women will be excluded; women of childbearing potential must have a negative pregnancy test within  days of initiation of treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within  days of treatment.
Negative urine or blood pregnancy test for women of childbearing potential
Negative pregnancy test within  days prior to commencement of dosing in premenopausal women, women of non childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year
Pregnant or breast-feeding patients; women of childbearing potential must have a pregnancy test performed a maximum of  days before start of treatment, and a negative result must be documented before start of treatment
Negative serum pregnancy test within  days prior to commencement of dosing in women of childbearing potential
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment.
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Pregnant or lactating - women of childbearing potential should use appropriate precautions to avoid becoming pregnant; females of childbearing potential must have a negative urine or serum pregnancy test within  days of study treatment start
Women of childbearing potential must have a negative serum or urine pregnancy test within  days; women of childbearing potential and men must agree to use contraception at study entry and for the duration of active study treatment
A negative urine pregnancy test is required within  week for all women of childbearing potential prior to enrolling on this trial
Are pregnant or breast-feeding. In women of childbearing potential, a negative serum pregnancy test is required prior to study treatment.
Negative pregnancy test in women of childbearing age
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
For women of childbearing age, a negative pregnancy test performed within  days of surgery
Women of childbearing potential must have a negative serum or urine pregnancy test performed within  days prior to FDG-PET-MRI
A negative urine pregnancy test is required within  week for all women of childbearing potential prior to enrolling on this trial
Women of childbearing potential must have a negative serum pregnancy test within  days prior to study entry
Women of childbearing potential must have a negative serum or urine pregnancy test within  weeks prior to initiation of therapy
A negative urine pregnancy test is required within  week for all women of childbearing potential prior to enrolling on this trial
Negative pregnancy test (urine or serum), within  day prior to day  of FOLFIRI in women of childbearing potential
For women of childbearing potential, negative urine or serum pregnancy test within  weeks prior to study entry
Women of childbearing potential who are not using an effective method of contraception are excluded; women of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to administration of SRS
Pregnant women will not be eligible; women of childbearing potential must have a negative pregnancy test before starting therapy
Negative serum pregnancy test result within  days prior to study drug among women of childbearing potential
Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within  days prior to study initiation.
Women of childbearing potential must have a negative pregnancy test within  days of starting treatment
Childbearing age women with negative pregnancy test
Women of childbearing potential who have a negative pregnancy test within  days of the first dose of sorafenib in this long term extension program.
Pregnant women or women of childbearing potential and not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential; no breast-feeding while on study.
. Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to start of study drug administration.
Pregnant or breastfeeding - The agents used in this study fall under Pregnancy Category D - Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. Women of childbearing potential must have a negative pregnancy test (urine or serum) within  days of study drug administration
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to initiation of treatment AND confirmed prior to initiation of treatment on day 
A negative urine pregnancy test is required within  week for all women of childbearing potential prior to enrolling on this trial
Pregnant or lactating women; pregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy test per standard of care prior to the surgery for tumor removal; a second pregnancy test must be performed  days prior to the first vaccination and must be negative; breastfeeding should be discontinued if the mother is treated on study
Negative urine or serum pregnancy test for women of childbearing potential within  days prior to study entry
Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within  days prior to initiation of study drug
Negative pregnancy test (either urine or serum) within  days prior to randomization for all women of childbearing potential (above)
Negative serum pregnancy test within  days of treatment initiation with ibrutinib in women of childbearing potential (WOCBP)
Pregnant women are excluded from this study; women of childbearing potential must have a negative pregnancy test
Evidence of non-child-bearing status for women of childbearing potential; negative urine or serum pregnancy test within  days of study treatment, confirmed prior to treatment on day 
Women of childbearing potential must have a negative serum or urine pregnancy test within  days of the administration of the first study treatment; women must not be lactating
Women of childbearing potential must have a negative pregnancy test performed within  days prior to the start of study drug
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within  days prior to start of study treatment
Women of childbearing potential must have a negative serum pregnancy test within  days of the first dose of study treatment
Women of childbearing potential (defined as having a menstrual cycle within the past  months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening
Women of childbearing potential (defined as having a menstrual cycle within the past  months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of starting the vemurafenib
For women of childbearing potential, a negative serum or urine pregnancy test
Negative serum pregnancy test in women of childbearing potential within  weeks of study
Premenopausal women must have a negative serum pregnancy test, including women who have had a tubal ligation and for women less than  months after the onset of menopause
Women of childbearing potential must have a negative serum pregnancy test within  days prior to randomization, and must not be breastfeeding and must agree to use contraceptive for duration of study.
Women of childbearing potential (WOCBP) with negative serum or urine pregnancy test within  days of day  (D) of treatment
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
Women of childbearing age with a negative pregnancy test documented prior to enrollment
Patients with a negative pregnancy test (urine or serum) must be documented within  days of starting treatment for women of childbearing potential (WOCBP)
Women of childbearing age with a negative pregnancy serum test documented prior to enrollment
A urine pregnancy test (within  days of enrollment date) is required for women with childbearing potential
Negative pregnancy test for women of childbearing potential (<  years of age) as per institutional policy
Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within  days prior to start of IPs
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to receiving study agents
Negative urine or serum pregnancy test done =<  days prior to registration/randomization, for women of childbearing potential only\r\n* NOTE: in the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on study
Women of childbearing potential must have a negative pregnancy test performed within  days of the start of study drug administration
Negative pregnancy test within  days prior to starting the study premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year
Women of childbearing potential (WOCBP) must have negative pregnancy test within  days prior to day  (D) of treatment
If patient is of childbearing potential, she must have a negative blood or urine pregnancy test within  days of surgical treatment on study
A positive serum pregnancy test within  days prior to treatment in women of childbearing potential
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum pregnancy test within  days before the start of the treatment; women of childbearing potential may have a urine pregnancy test, instead of a serum pregnancy test; if either the serum or urine pregnancy test is equivocally negative the patient will be eligible for the protocol; women of childbearing potential must agree to use an adequate method of contraception during the study until  days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until  days after the last treatment
Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than  months after the onset of menopause
Women of childbearing potential must have a negative serum/urine pregnancy test
Women of childbearing potential (WOCBP) must have a negative pregnancy test within  days of receiving study medication
Negative serum pregnancy test within  days of commencement of treatment in premenopausal women
Women of childbearing potential must have a negative pregnancy test within  days of starting treatment
Pregnancy or breast feeding - women of childbearing potential must have a negative pregnancy test within  days of study enrollment
Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.
Women of childbearing potential with negative serum pregnancy test prior to randomisation
Women of childbearing potential must have a negative, qualitative serum pregnancy test =<  weeks prior to study entry
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of pazopanib treatment and both men and women must be willing to use adequate contraception
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to treatment
Pregnant or breastfeeding patients; women of childbearing potential must have a pregnancy test performed a maximum of  days before start of FOLFIRI treatment, and a negative result must be documented before start of treatment
Women of childbearing potential must have a negative serum pregnancy test at the time of transition to this study and before the first dose of study treatment
Women of childbearing age must have a negative serum or urine pregnancy test prior to the initiation of study drug.
Women of childbearing potential must have a negative serum or urine pregnancy test upon study entry
Women of childbearing potential need to have a negative serum pregnancy test at the time of therapy
Serum or urine pregnancy test (for women of childbearing potential) negative =<  days of starting treatment
Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within  days of study treatment and confirmed prior to treatment on Day ;
Women of childbearing potential must have a negative pregnancy test performed within  weeks prior to the start of treatment
Women of childbearing age must have a negative serum pregnancy test, and adequate contraception method(s) must be documented
Negative pregnancy test in women of childbearing potential (premenopausal or less than  months of amenorrhea post-menopause, and who have not undergone surgical sterilization), no more than  days before the first dose of study treatment
Women of childbearing potential (WOCBP) must have negative pregnancy test within  days prior to day  (D) of treatment
Pregnant or breastfeeding; a negative blood-pregnancy test is required for women of childbearing potential (WOCBP) within  days prior to her computed tomography (CT) stimulation for treatment planning
Women of childbearing potential must have a negative serum pregnancy
Negative urine pregnancy test within  days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without urine pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year
Women of childbearing potential must have a negative pregnancy test performed within  days prior to the start of treatment
Negative serum or urine pregnancy test within  days prior to study treatment in premenopausal women and women </=  years after menopause (menopause is defined as amenorrhea for >/=  years)
For women of childbearing potential, a negative serum pregnancy test completed prior to any radiation therapy
Negative pregnancy test for women of childbearing potential within  days of starting study treatment
Pregnant or breast-feeding women; women of childbearing potential must have a negative urine or serum pregnancy test within  days of start of treatment
Negative urine pregnancy test for women of childbearing potential
Adequate bone marrow function Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within  days prior to study initiation.
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Women of childbearing potential must have a negative serum pregnancy test within  days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least  days after the last administration of pralatrexate.
For women of childbearing potential, have a negative pregnancy test (serum or urine) on Day  prior to initiating study treatment.
Serum or urine pregnancy test negative within  weeks for women of childbearing potential
Women of childbearing potential must have a negative pregnancy test (urine or serum) performed within  days prior to the start of study drug.
Negative pregnancy test (urine dipstick or serum) for women of childbearing potential within  weeks prior to registration
Negative serum or urine pregnancy test must be obtained within  days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administration
Women of childbearing potential must have a serum pregnancy test performed within  days prior to the first day of study drug dosing.
Women of childbearing age must have a negative urine pregnancy test
Women of childbearing potential (WOCBP) must have a negative pregnancy test performed prior to the start of study drug
Negative serum pregnancy test within  days prior to starting study treatment in premenopausal women and women less than (< ) years after the onset of menopause
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to the start of SL- treatment.
Women of childbearing potential must have a negative serum pregnancy test within  days of first dose of study treatment.
Women of childbearing potential must have a blood or urine pregnancy test performed a maximum of  days before start of study treatment, and a negative result must be documented before start of study treatment
Women of childbearing potential (WOCBP) who have a positive serum pregnancy test within  days of the first administration of oral dasatinib
Women of childbearing potential must have a negative urine pregnancy test performed within  days before start of study treatment
Negative results of serum pregnancy test for premenopausal women of reproductive capacity and for women <  months after entering menopause
Women of childbearing potential must have a negative urine or serum pregnancy test within  days prior to administration of everolimus
Women of childbearing potential must have a negative serum pregnancy test before study entry.
Negative serum or urine pregnancy test for women of childbearing potential only
Negative serum pregnancy test within  days before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to treatment
Pregnant or nursing women; a negative pregnancy test (serum or urine) =<  days prior to starting study treatment
Women of childbearing potential must have a negative pregnancy test performed within  days prior to the start of study drug
Negative serum pregnancy test within  days prior to commencement of dosing in women of childbearing potential
Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =<  days prior to registration and confirmation they are not nursing is required
Premenopausal women (including women who have had a tubal ligation and for women less than  months after the onset of menopause) must have a negative serum pregnancy test
Non-pregnant; women of childbearing potential must have a negative pregnancy test to participate in this study
If the patient is of childbearing potential, the patient must have a negative blood or urine pregnancy test within  days of surgical treatment on study
Negative pregnancy test (serum or urine) done =<  days prior to registration, for women of childbearing potential only (determined per clinician discretion)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment.
Negative (serum or urine) pregnancy test, for women of childbearing potential only
Negative serum pregnancy test within  days prior to study treatment in premenopausal women and women less than or equal to (<=)  months post-menopause. Postmenopausal state is defined as amenorrhea for greater than (>)  months.
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women >=  years of age who have not had a menstrual period in the past year; and women who have had a hysterectomy, both ovaries removed, or a tubal ligation; will not be required to have a pregnancy test
Women of childbearing potential (WCBP) must have a negative urine pregnancy test within  days prior to the first study intervention
Negative pregnancy test at time of signing consent for women of childbearing potential
Women of childbearing potential must have a negative urine or serum pregnancy test
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women who are >=  years old or who have had a hysterectomy, both ovaries removed, or a tubal ligation will not be required to have a pregnancy test
Women of childbearing age with a negative pregnancy test documented prior to enrollment
A negative serum pregnancy test at baseline, but within  days of randomization, for persons of childbearing potential only
Not pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =<  days prior to registration/randomization for women of childbearing potential
A negative serum pregnancy test within  days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for ?  year or who have a history of hysterectomy or surgical sterilization)
Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative pregnancy test or who are lactating
Women of childbearing potential (WCBP): negative serum pregnancy test, obtained within  days prior to PET scan
Negative pregnancy test within  days prior to starting the study in premenopausal women; women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year
Patients of childbearing potential must have a negative urine or serum pregnancy test within  days prior to PET/CT imaging per institutions standard of care.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test no more than  days prior to FDOPA injection
Women of childbearing age must have a negative blood pregnancy test
Women of childbearing potential must have a negative serum or urine pregnancy test performed within  days prior to first PET/MRI
Women must have a negative serum pregnancy test within  days prior to the first dose of study drug or be surgically or biologically sterile or postmenopausal
Women of childbearing potential must have a negative serum or urine pregnancy test within  days prior to enrollment.
Pregnant or breastfeeding (negative serum or urine pregnancy test required for women of childbearing potential), or unable to maintain use of contraception while on study and for  days after the last dose of avelumab
Women of childbearing potential will be required to have a urine pregnancy test
Women of childbearing potential must have a negative pregnancy test prior to the administration of protocol specified interventions
Negative urine pregnancy test for women of childbearing potential within  days of baseline [D]phe dosing
Negative serum pregnancy test within  days prior to study treatment in premenopausal women and women <=  years after start of menopause
Pregnant or lactating women; all pre-menopausal women being screened must have a negative serum pregnancy test within  days prior to commencement of dosing; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >=  year
Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge
For women of childbearing potential, negative serum pregnancy test within  days of enrollment
Negative serum or urine pregnancy test must be obtained within  days prior to the first dose of study drug in women of childbearing potential. Negative results must be available prior to study drug administration. Pregnancy tests will be repeated regularly during treatment